Hyperlipidemia Management in Proprotein Convertase Subtilisin- Kexin Type 9 (PCSK 9) Inhibitors Era

Abstract

Significant improvement in control of cardiovascular risk factors has been driven by performance measurement that focused on attainment of specific risk factor thresholds for blood glucose, lipids and blood pressure. Diet, statin and ezetimibe have reasonably controlled hyperlipidemia. However the discovery of proprotein convertase subtilisin-kexin type 9 inhibitors has given new hope of reaching the target lipid profile especially in the high-risk group and familial hypercholesterolemia. Herewith we reviewed the current data and explore the cardiovascular prevention effect of this group.